These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12971645)

  • 1. Optimal scan time for evaluating pancreatic disease with positron emission tomography using F-18-fluorodeoxyglucose.
    Nakamoto Y; Saga T; Higashi T; Ishimori T; Kobayashi H; Ishizu K; Sato N; Mamede M; Sakahara H; Imamura M; Konishi J
    Ann Nucl Med; 2003 Jul; 17(5):421-6. PubMed ID: 12971645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
    Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
    Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.
    Diederichs CG; Staib L; Vogel J; Glasbrenner B; Glatting G; Brambs HJ; Beger HG; Reske SN
    Pancreas; 2000 Mar; 20(2):109-16. PubMed ID: 10707924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
    Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI.
    Donati OF; Hany TF; Reiner CS; von Schulthess GK; Marincek B; Seifert B; Weishaupt D
    J Nucl Med; 2010 May; 51(5):692-9. PubMed ID: 20395324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
    Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
    J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.
    Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Tsutsui K; Wakabayashi H; Ohkawa M
    Nucl Med Commun; 2005 Oct; 26(10):895-901. PubMed ID: 16160649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of PET in the detection of liver metastases from pancreatic tumours.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Imamura M; Konishi J
    Clin Radiol; 1999 Apr; 54(4):248-52. PubMed ID: 10210345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of liver metastases from pancreatic cancer using FDG PET.
    Fröhlich A; Diederichs CG; Staib L; Vogel J; Beger HG; Reske SN
    J Nucl Med; 1999 Feb; 40(2):250-5. PubMed ID: 10025831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
    Nakamoto Y; Osman M; Wahl RL
    Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
    Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
    Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
    Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
    Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.